Rosuvastatin enhances the efficacy of venetoclax-azacitidine in older acute myeloid leukemia patients via reducing T-cell exhaustion
Adding a common cholesterol drug to a standard leukemia treatment helped older patients achieve higher remission rates and reduced immune cell exhaustion.
This multicenter Phase II trial (ChiCTR 2500111931) evaluated rosuvastatin added to venetoclax-azacitidine in older/unfit AML, yielding a composite complete remission rate of 72.2% and deep MRD negativity in 84.6% of responders. Mechanistically, rosuvastatin significantly reduced PD-1⁺CD4⁺ and PD-1⁺CD8⁺ T-cell exhaustion, providing a novel immune-based rationale for statin co-administration with HMA-based regimens.
What the study was
- Study design
- Multicenter Phase II clinical trial
- Population
- Older/unfit AML patients receiving first-line venetoclax-azacitidine
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Cancer Immunology, Immunotherapy
Why it surfaced
Phase II multicenter trial demonstrating statin-mediated reversal of T-cell exhaustion to enhance venetoclax-azacitidine efficacy in older/unfit AML — a novel immunomodulatory mechanism. CRc 72.2% and deep MRD negativity in 84.6% of responders represents a meaningful improvement over historical two-drug venetoclax-azacitidine benchmarks. High unmet need population (older/unfit AML).
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.